Growth in Leading Regional and National Markets – North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico, Teva, Novartis, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy’s Laboratories Limited, Apotex
The generic drugs market is estimated to have reached $257.3bn in 2018 and is expected to grow at a CAGR of 8.8% in the first half of the forecast period. Asia-Pacific held 31% of the generic drugs market in 2018.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 246-page report you will receive 66 tables and 84 figures– all unavailable elsewhere.
The 246-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Generic Drugs Market forecasts from 2019-2029
• Generic Drugs Market forecasts from 2019-2029 by Regional and National Market: • North America: U.S., Canada • Europe: Germany, France, UK, Italy, Spain, Rest of Europe • Asia-Pacific: Japan, China, Australia, South Korea, India, Rest of Asia-Pacific • Middle East & Africa: South Africa, Saudi Arabia, UAE, Rest of Middle east & Africa • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
• Profiles and generic drugs revenue forecasts from 2019-2029 of these selected leading companies: • Abbott • Apotex • Aspen • Dr. Reddy’s Laboratories Limited • Fresenius Kabi • Mylan • Novartis • Pfizer • Sanofi • Sun Pharma • Teva
• Qualitative analysis of the generic drugs market: • SWOT Analysis of the generic drugs market • Porter’s Five Forces Analysis of the generic drugs market • Discussion on factors that drive and restrain the generic drugs market
• Key Questions Answered by This Report: • How is the global market for generic drugs evolving? • What are the major factors driving and restraining the generic drugs market dynamics? • What were the market shares of the leading national markets in the global generic drugs market in 2018? • How will each of these national markets grow over the forecast period and how much revenue will these markets account for by 2029? • How will the market shares for each of the national markets develop from 2018 to 2029? • Which particular national markets will be the main drivers of growth in the global market for generics from 2018 to 2029? • How will political and regulatory factors influence the regional markets and submarkets? • What are the predictions for partnerships, consolidation for existing players and the potential prospects for new market entrants? • How will the industry sector evolve as legislations around patents and patent expiries change during the period between 2018 and 2029?
Visiongain’s study is intended for anyone requiring commercial analyses for the Generic Drugs Market. You find data, trends and predictions.
Buy our report today Global Generic Drugs Market Analysis : Forecast From 2019-2029 Growth in Leading Regional and National Markets – North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico, Teva, Novartis, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy’s Laboratories Limited, Apotex.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Global Generic Drugs: Market Overview
1.2 Global Generic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is this Report for?
1.7 Methodology
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. An Introduction to Generic Drugs
2.1 An Introduction to the Rise of Generic Drugs
2.2 What Are Generic Drugs?
2.2.1 Generic Active Ingredients
2.3 A Brief Overview of the Pharmaceutical Industry
2.3.1 Brief History of Generic Drugs
2.3.2 The Hatch-Waxman Act: The Rise of Generics
2.4 Demonstrating Bioequivalence: A Major Factor in Approving Generics
2.5 Types of Generics – Authorised, Branded and Unbranded
2.6 Complex Generics
2.7 Classification of Generic Drugs Markets
2.8 Is Generic Substitution Bad News for Big Pharma Business?
2.8.1 The 'Ever greening' of Pharmaceutical Products
2.9 Regulation of Generic Drugs
2.9.1 Regulation in the US
2.9.1.1 Obtaining FDA Approval: NDAs and ANDAs
2.9.1.2 The Hatch-Waxman Act Title I: Promotion of Generic Drugs
2.9.1.3 The Hatch-Waxman Act Title II: Incentives for the Branded Industry
2.9.1.4 How Hatch-Waxman Act Impacted the US Pharmaceuticals Market?
2.9.1.5 How Market Entry Timing Influences Product Success
2.9.2 Regulation in Europe
2.9.2.1 EU Marketing Approval Procedures
2.9.2.2 The 8+2+1 Rule: EU Data Exclusivity
2.9.2.3 Supplementary Protection Certificates
2.9.2.4 Variation in Drug Development Regulations between European Countries
2.9.2.5 The Move towards Harmonisation of Standards
2.9.2.6 The Impact of Europe’s Unitary Patent System on Generic Drugs
2.9.2.7 In or Out: Unitary Patent Strategy for European Generic Drug Manufacturing
2.9.3 Regulation in Japan
2.9.4 Regulation in China
2.10 Compulsory Licensing
2.11 Market Definition and Scope of this Report
2.11.1 Market Sizing and Revenue Reporting
3. Generic Drugs Market Forecast 2019-2029
3.1 The Global Generic Drugs Market: Market Overview
3.1.1 Segmenting the Global Generic Drugs Market
3.2 The Rise of the Global Generic Drugs Market in 2019
3.3 The Global Generic Drugs Market: Sales Forecast 2019-2029
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033
The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.
The global Stem Cell Therapy Contract Manufacturing market was valued at US$2,495.1 million in 2022 and is projected to grow at a CAGR of 12.4% during the forecast period 2023-2033.
Immuno-Oncology Clinical Trials market is valued at US$6,849.8 million in 2023 and is projected to grow at a CAGR of 11.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
